Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
|
|
- Joshua Waters
- 6 years ago
- Views:
Transcription
1 Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
2 Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe advantages and disadvantages to DOAC use Compare efficacy and safety of DOACs with warfarin Describe adverse effect profile of DOACs Determine which patients are good candidates for DOAC therapy vs warfarin
3
4 Warfarin
5 Kinetics Absorption: complete Distribution: 99% protein binding Only FREE warfarin is available for use at VKORC1 Metabolism: broken down by cytochrome P450 enzymes in the liver R-warfarin primary via 3A4 S-warfarin (SERIOUS WARFARIN) primary via 2C9 2C9 inhibitors will RAISE INR significantly. 3A4 inhibitors will RAISE INR to a lesser extent. Elimination: 92% renal LOTS of reasons why genetics can have effects on warfarin
6 Factors that affect warfarin dosing Body size Age Renal function Liver function Drug-drug interactions Dietary vitamin K intake Acute & chronic illness Smoking Alcohol Physical activity Genetics Warfarin manufacturer
7
8 Warfarin PROS Effective Inexpensive INR monitoring Reversible CONS Variable Dosing INR Monitoring Drug-drug interactions Lifestyle interactions Requirement for anticoagulation care provider
9 Other Oral Options?
10 TSOACs / DOACs / NOACs Current favorite acronym: DOAC (Direct Oral AntiCoagulant) Mechanisms of action DIRECT binding to active sites of factor II (thrombin) or Xa DabigaTran (Pradaxa) T for THROMBIN rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa) factor Xa Cost per 30 days = $ Reversible?
11 The Clotting Cascade
12 What can we use DOACs for? The Big Three: (non-valvular) Atrial Fibrillation Treatment of Venous Thromboembolism (VTE) Prevention of Recurrent VTE Post-joint-replacement VTE Prophylaxis Still Being Investigated: VTE Associated with Cancer VTE Associated with Hypercoagulable State Patients with Bioprosthetic Heart Valves With Dual Antiplatelet Therapy (DAPT) Not For Use In: Mechanical Heart Valves Left Ventricular Assist Devices
13 Dabigatran (Pradaxa) Absorption: 3-7% bioavailable Dosage form relies on low gastric ph No opening/crushing capsules
14 Dabigatran (Pradaxa) Absorption: 3-7% bioavailable Dosage form relies on low gastric ph No opening/crushing capsules Distribution: 35% protein bound Metabolism: metabolized readily after absorption from dabigatran etexilate to the active moiety, dabigatran Gut: p-glycoprotein Elimination: 80% renal t 1/2 = hours in healthy people
15 Dabigatran (Pradaxa ) Dosage Forms Capsules: 150 mg, 110 mg, 75 mg Do not break, chew, or open capsules before administration. Keep in original bottle. Monitoring Serum creatinine Adverse Effects Risk of bleeding Dyspepsia (11.3%)
16 Dabigatran in Atrial Fibrilation: RE-LY P < superiority
17 Dabigatran in Atrial Fibrilation: RE-LY P = 0.31 Note: Dabigatran 150 mg increased the rate of GI bleeding (p<0.001), decreased ICH (p<0.001) when compared to warfarin.
18 Dabigatran in VTE: RE-COVER Rate of Recurrent VTE 5 P < for noninferiority warfarin (INR 2-3) 2.4 dabigatran 150mg BID
19 Dabigatran in VTE: RE-COVER Rate of Major Bleeding warfarin (INR 2-3) 1.6 dabigatran 150mg BID
20 Other Clinical Trials for Pradaxa RE-ALIGN: Mechanical Heart Valves RE-SONATE: prevention of recurrent VTE vs placebo RE-MEDY: prevention of recurrent VTE vs warfarin RE-NOVATE: prevention of VTE after hip replacement surgery (vs enoxaparin)
21 Dabigatran Dosing VTE prevention after hip-replacement surgery Crcl 30ml/min or above Crcl less than 30ml/min Crcl 50ml/min or above with P-gp inhibitor Crcl less than 50ml/min with P-gp inhibitor 220mg daily Avoid 220mg daily Avoid
22 Xa Inhibitors
23 Rivaroxaban (Xarelto) Absorption: % bioavailable Better absorption with smaller doses & with food Distribution: 92-95% protein binding Metabolism: Gut: p-glycoprotein Liver: CYP450 3A4 Elimination: 66% renal T 1/2 : 5-12 hours
24 Rivaroxaban (Xarelto ) Dosage Forms Tablets: 20 mg, 15 mg, 10 mg Breakable/Crushable Monitoring Renal function Adverse Effects Bleeding risk
25 Rivaroxaban in Atrial Fib: ROCKET-AF Rate of stroke or systemic embolism (%) P<0.001 for non-inferiority Warfarin Rivaroxaban
26 Rivaroxaban in Atrial Fib: ROCKET-AF Rate of major bleeding (%) Warfarin Rivaroxaban
27 Rivaroxaban in VTE: EINSTEIN Rate of Recurrent VTE P<0.001 for noninferiority 3 P=0.003 for noninferiority Rivaroxaban Warfarin Einstein DVT Einstein PE
28 Rivaroxaban in VTE: EINSTEIN 2.5 Rate of Major Bleeding (%) P=0.21 P= Rivaroxaban Warfarin Einstein DVT Einstein PE
29 Other Rivaroxaban Clinical Trials Einstein Choice: Rivaroxaban 10mg daily for extended prophylaxis of VTE RECORD 1-4: post-joint-replacement VTE prophylaxis PIONEER: low-dose riva + P2Y12 vs. ultra-low-dose riva + DAPT vs. VKA + DAPT for post-pci afib patients
30 Rivaroxaban Dosing
31 Apixaban (Eliquis) Absorption: 50% bioavailable No effect of food Distribution: 92-95% protein binding Metabolism: Gut: p-glycoprotein Liver: CYP450 3A4 Elimination: 27% renal T 1/2 : 7-15 hours
32 Apixaban (Eliquis ) Dosage Forms Tablets: 5 mg, 2.5 mg Breakable, crushable May be administered without regard to food Monitoring Serum creatinine Adverse Effects Risk of bleeding
33 Apixaban in Atrial Fibrillation: ARISTOTLE Rate of Stroke or Systemic Embolism (%) P=0.01 for superiority Warfarin Apixaban
34 Apixaban in Atrial Fibrillation: ARISTOTLE Rate of Major Bleed (%) 3 P< Warfarin Apixaban
35 Apixaban in VTE: AMPLIFY & AMPLIFY-EXT Rate of Recurrent VTE (%) in AMPLIFY Warfarin P<0.001 for non-inferiority 2.3 Apixaban Rate of Recurrent VTE (%) in AMPLIFY-EXT Apixaban 2.5mg BID P<0.001 for superiority of both doses vs placebo Apixaban 5mg BID 8.8 Placebo
36 Apixaban in VTE: AMPLIFY & AMPLIFY-EXT Rate of Major Bleeding (%) in AMPLIFY P< Warfarin Apixaban Rate of Major Bleeding (%) in AMPLIFY-EXT Apixaban 2.5mg BID Apixaban 5mg BID Placebo
37 Apixaban: Other Clinical Trials AVERROES: atrial fib trial vs. ASA ADVANCE 1-3: post-joint-replacement VTE prophylaxis
38 Apixaban Dosing Extended VTE treatment Without concomitant P- gp/cyp3a4 inhibitor With concomitant P- gp/cyp3a4 inhibitor 2.5mg BID Avoid
39 Edoxaban (Savaysa) Absorption: 62% bioavailable No effect of food Distribution: 55% protein binding Metabolism: Gut: p-glycoprotein Elimination: 50% renal T 1/2 : hours
40 Edoxaban (Savaysa ) Dosage Forms Tablets: 15mg, 30mg, 60mg May be administered without regard to food Monitoring Renal function Adverse Effects Risk of bleeding
41 Edoxaban Clinical Trials ENGAGE AF TIMI 48 (atrial fibrillation) Efficacy: non-inferior to warfarin Safety: less bleeding than warfarin HOKUSAI (VTE treatment) Efficacy: non-inferior to warfarin Safety: less bleeding than warfarin
42 Edoxaban Dosing Indication Dose Crcl 15-50ml/min Atrial fibrillation DVT/PE Crcl >95 ml/min Body weight < 60kg 60mg daily 30mg daily Do not use No adjustment 60mg daily (after 5-10 days of parenteral) 30mg daily No adjustment 30mg daily P-gp inhibitor No adjustment 30mg daily Post-joint replacement 30mg daily
43 DOAC Trial Data Summary Atrial Fibrillation DVT/PE treatment stroke prevention (compared to warfarin) rates of bleeding (compared to warfarin) rate of recurrent VTE (compared to LMWH bridged warfarin) rates of bleeding (compared to warfarin) Pradaxa (dabigatran) superior same same same Xarelto (rivaroxaban) same same same same Eliquis (apixaban) superior superior same superior Savaysa (edoxaban) same superior same superior
44 DOAC Drug-Drug Interactions Dabigatran (substrate of p-glycoprotein) Inducers (rifampin): avoid co-administration Inhibitors (dronedarone, ketoconazole): dose reduce or avoid (see prescribing info) Verapamil: separate by 2 hours Xa Inhibitors (substrates of CYP 3A4 & p-gp) Dual inducers (carbamazepine, phenytoin, phenobarb, rifampin, St. John s wort): avoid coadministration Dual inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin): reduce dose or avoid (see prescribing info)
45 Reversal Agents Supportive therapies (all anticoagulants) Fresh frozen plasma, fluids, blood products Prothrombin complex concentrates (all anticoagulants) 3-Factor: factors II, IX, X 4-Factor: factors II, VII, IX, X Warfarin: Vitamin K Dabigatran: idarucizumab (Praxbind) Xa Inhibitors: andexanet alfa (not available yet)
46 Peri-Procedural Management PLEASE DON T BRIDGE DOACs!!
47 The Ideal DOAC Patient Diagnosed with one of the Big Three Good kidney function Compliant with medications Average body size Not on strong p-gp or 3A4 inhibitors or inducers History of unstable INRs not related to medication noncompliance Commercially insured
48 Patient-Centered Care Indication & clinical data Patient preferences Don t make assumptions Utilize manufacturer assistance when appropriate Beware the donut hole
49 Clinical References at Your Fingertips Anticoagulationtoolkit.org European Heart Rhythm Associate Practical Guide on the Use of Non-Vitamin K Antagonist Anticoagulants in Patients with Non- Valvular Atrial Fibrillation
50 References Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January Connolly SJ et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. NEJM. 2009; 361: Schulman S et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. NEJM 2009; 361: Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November Patel MR. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. NEJM 2011; 365: The Einstein Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. NEJM 2010; 363: Eliquis [Package insert]. Princeton, NJ: Bristol-Myers Squibb Company. July, Granger CB et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2011; 365: Agnelli G et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. NEJM 2013; 369: Agnelli G et al. Apixaban for Extended Treatment of Venous Thromboembolism. NEJM 2013: 368; Savaysa [package insert]. Parsippany, NJ. Daiichi Sankyo, Inc Giugliano RP et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2013; 369: The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. NEJM 2013; 369: ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. JACC 2017 epub ahead of print. Heidbuchel H et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5):
New Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationto a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching
Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationMaster Class: DOAC Drug Interactions April 20, 2017
Master Class: DOAC Drug Interactions April 20, 2017 Sara R. Vazquez, PharmD, BCPS, CACP Clinical Pharmacist University of Utah Health Thrombosis Service Disclosures Financial Disclosures: none Off-label/investigational
More information04/13/2015. Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement. Abbreviations. Learning Objectives TSOACS
1 2 Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement I have nothing to disclose concerning possible financial or personal relationships with commercial entities
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationSupplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationTechnician Objectives. Pharmacist Objectives. Replacing Warfarin. Gaps in Practice. Target-Specific Anticoagulants: Clinical Update and
Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart, PharmD, BCPS September 13,2014 Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart,
More informationDr Calum Young Cardiologist Tauranga
Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationAnticoagulation in 2014: Using the New Agents Safely
Anticoagulation in 2014: Using the New Agents Safely Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationUpdate with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist
Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationGetting the Most from DOAC Therapy:
Getting the Most from DOAC Therapy: Minimizing Risk and Maximizing Adherence Brent N. Reed, Pharm.D., BCPS AQ Cardiology University of Maryland School of Pharmacy Stuart T. Haines, Pharm.D., BCPS, BCACP,
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Anticoagulatns New Agents, Reversal and Bridging William
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationAcute Care: Understanding Direct Oral Anticoagulants (DOACs)
Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation
More informationThe (Hopefully) Bloodless Battle for Safe Use of DOACs. Gale E. Garmong, PharmD Clinical/Staff Pharmacist Klingensmith s Drug Stores
The (Hopefully) Bloodless Battle for Safe Use of DOACs Gale E. Garmong, PharmD Clinical/Staff Pharmacist Klingensmith s Drug Stores Objectives At the completion of this activity, the participant will be
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationKelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY
Jedi Training 101: Mind-tricks & Evidence -Based Approaches to Combating Clinical Controversies in Anticoagulation Therapy Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY LEARNING
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More information